Has the conference call already come and gone without stating any Rett updates or lack there of and completely glossed over the entire indication? I must of missed it this morning. In the case the conference call is actually this afternoon, maybe we should wait to see what it produces before claims about delays are made.
"Why no enrollment update for the 20 patient Rett trial? What is taking so long and why is the company not updating?"
From this morning cinical update:
To offer all participants access to ANAVEX®2-73 (blarcamesine) after completion of the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett syndrome study1 and the AVATAR Rett syndrome study2, 12-week and 48-week open-label extension studies, respectively were initiated. Currently 90% and 100% of eligible participants have continued into the corresponding extension studies. The international EXCELLENCE Rett syndrome study of ANAVEX®2-73 (blarcamesine) in pediatric patients was approved by the Australian Human Research Ethics Committee and is scheduled to initiate early 2020.
News 
Market Data 
Discover 
AI
